In July, China launched an emergency vaccine program. It provides for the vaccination of workers in vital sectors of the economy with three candidate vaccines. Vaccinations are being carried out despite the fact that clinical trials have not yet been completed and the safety and efficacy of the vaccines has not been proven, according to Reuters.
Sinopharm said no serious adverse reactions were reported in those who received the vaccine on an emergency basis. The program is known to use three vaccines: two are being developed by Sinopharm's subsidiary China National Biotec Group (CNBG), and the third is being developed by Sinovac Biotech.
Chinese vaccines are also being tested abroad, with 60,000 people receiving them in Phase 3 clinical trials. According to representatives of the developers, among the diplomats, students and other Chinese citizens who went abroad to work or study, no one was infected.
Meanwhile, the Danish Ministry of Health announced that the strain of coronavirus that originated among minks in fur farms and from there passed to humans is likely to have died out. "Since September 15, no cases of infection with the Cluster 5 strain have been detected, so the State Blood Serum Institute believes that this option is most likely extinct," the ministry said in a statement.
News has surfaced about another promising vaccine being developed by scientists at Oxford University and the pharmaceutical company AstraZeneca. Phase 2 trial data, published in The Lancet, suggests the vaccine elicits a robust immune response in all three age groups - 18-55, 56-69, and 70 and older. Moreover, the vaccine was less likely to cause side effects in older people than in the younger group. It is also known that the Oxford vaccine will have at least one important advantage over the Pfizer and Moderna vaccines: it can be stored at temperatures between 2 ° C and 8 ° C.